FLUTROPIUM

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H29FNO3
Molecular Weight	398.4904
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

C[N@@+]1(CCF)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(C3=CC=CC=C3)C4=CC=CC=C4

InChI

InChIKey=OATDVDIMNNZTEY-XWALJWNASA-N

InChI=1S/C24H29FNO3/c1-26(15-14-25)20-12-13-21(26)17-22(16-20)29-23(27)24(28,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,20-22,28H,12-17H2,1H3/q+1/t20-,21+,22+,26?

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6139497
Curator's Comment: description was created based on several sources, including: http://en.pharmacodia.com/web/drug/1_10230.html | https://www.ncbi.nlm.nih.gov/pubmed/7886652 | https://www.ncbi.nlm.nih.gov/pubmed/2431695

The anticholinergic agent Flutropium is a classic competitive antagonist of acetylcholine. In in vitro experiments it is more effective than atropine. A poor enteral absorption is to be expected; this can be concluded from the low relative effectiveness after oral administration. After local administration as an aerosol it is superior to atropine with regard to both effectiveness and duration of action. It is used in Japan to treat asthma and chronic obstructive pulmonary disease. Flutropium can be described as a preparation which is free of side effects.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 162 Target ID: CHEMBL2094109 Sources: http://en.pharmacodia.com/web/drug/1_10230.html \| http://www.chemdrug.com/article/8/3284/16419619.html	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic obstructive pulmonary disease 175 Sources: http://en.pharmacodia.com/web/drug/1_10230.html	Palliative		Approved 8583	FLUBRON Approved Use It has been used for the relief of symptoms of bronchial asthma and COPD.
Asthma 244 Sources: http://en.pharmacodia.com/web/drug/1_10230.html	Palliative		Approved 8583	FLUBRON Approved Use It has been used for the relief of symptoms of bronchial asthma and COPD.

Doses

Dose	Population	Adverse events
900 ug 1 times / day multiple, respiratory Studied dose Dose: 900 ug, 1 times / day Route: respiratory Route: multiple Dose: 900 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7886652/	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7886652/	Sources: https://pubmed.ncbi.nlm.nih.gov/7886652/

PubMed

Title	Date	PubMed
[Effects of flutropium bromide, a new antiasthma drug, with repeated administration on bronchomotor response and hepatic drug metabolizing enzymes].	1989-06	2567689
[Effects of flutropium bromide, a new antiasthma drug, on mediator release from mast cells and actions of mediators].	1988-02	2453423
Pharmacology of the anticholinergic bronchospasmolytic agent flutropium bromide.	1986-09	2431695
Synthesis of the bronchospasmolytic agent flutropium bromide and of some homologous and configuration isomeric compounds.	1986-08	3778552
Molecular and crystal structure of flutropium bromide.	1986-08	3778553
Effects of 8-(2-fluoroethyl)-3 alpha-hydroxy-1 alpha H, 5 alpha H-tropaniumbromide benzilate (Ba598Br) on allergy- and drug-induced asthmas.	1983-10	6139497

Patents

Sample Use Guides

In Vivo Use Guide

60 ug per puff

Route of Administration: Respiratory

In Vitro Use Guide

Unknown

Name

Type

Language

(8R)-8-(2-FLUOROETHYL)-3.ALPHA.-HYDROXY-1.ALPHA.H,5.ALPHA.H-TROPANIUM BENZILATE

Preferred Name

English

FLUTROPIUM

Common Name

English

Flutropium [WHO-DD]

Common Name

English

FLUTROPIUM CATION

Common Name

English

FLUTROPIUM ION

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29704